Showing 1 - 10 of 3,353
This paper examines the optimal content regulation of DTCA by comparing two forms of DTCA-product-specific and category-specific-and identifies a key tradeoff which underlies this policy debate. Our analysis suggests that the optimal form of DTCA depends crucially on the cost effectiveness of...
Persistent link: https://www.econbiz.de/10013329470
Persistent link: https://www.econbiz.de/10012197768
Persistent link: https://www.econbiz.de/10011708133
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Persistent link: https://www.econbiz.de/10011963838
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10012802183
Persistent link: https://www.econbiz.de/10012267512
pharmaceuticals to examine how incumbents respond to change in the threat of entry. In line with the entry deterrence motive …
Persistent link: https://www.econbiz.de/10012285099
This WTO working paper studies availability and affordability of new and innovative pharmaceuticals in a post-TRIPS era … the introduction of product patents in pharmaceuticals affect the likelihood of pharmaceutical firms to launch new and … finds that introduction of product patent for pharmaceuticals in the patent law has a positive effect on launch likelihood …
Persistent link: https://www.econbiz.de/10011992779
Persistent link: https://www.econbiz.de/10011734578